One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Koninklijke Philips N.V. logo
Koninklijke Philips N.V. PHG
$ 25.74 0.98%
report update icon

Quarterly report 2025-Q4
added 05-06-2026

Koninklijke Philips N.V. Balance Sheet 2025-2011 | PHG

Brief overview of Koninklijke Philips N.V.'s assets and capital

The review uses the five latest available annual reports between 2019 and 2025.

Assets changed little, standing at €27 billion initially and €26.9 billion at the end. The balance sheet stayed close to its former scale.

Liabilities grew more slowly than assets: -40.9% versus -0.3%. Expansion relied more on equity, improving funding quality.

Shareholders' equity accounts for 40.8% of assets, previously 46.7%. Dependence on liabilities is moderate.

The cash reserve occupies 10.4% of the balance sheet, previously 5.3%. It is one marker of short-term resilience.

Overall assessment

Koninklijke Philips N.V.'s financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.

Annual Balance Sheet Koninklijke Philips N.V.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - - - - 2.48 B 3.51 B 3.04 B 2.73 B 3.27 B 3.99 B 2.23 B 1.44 B 700 M 713 M

Long Term Debt

- - - - - 5.7 B 4.94 B 3.43 B 4.04 B 4.02 B 4.1 B 3.71 B 3.31 B 3.72 B 3.28 B

Long Term Debt Current

- - - - - - - 241 M - - - - - - -

Total Non Current Liabilities

8.45 B 8.79 B 9.06 B 9.47 B - 8.08 B 7.41 B 5.96 B 6.43 B 8.32 B 9.13 B 8.16 B 6.86 B 7.95 B 7.23 B

Total Liabilities

16 B 16.9 B 17.3 B - - 15.8 B 27 B 26 B 25.3 B 32.3 B 31 B 28.4 B 26.6 B -2 B -2.11 B

Deferred Revenue

- - - - - 1.24 B - - - - - - - - -

Total Assets

26.9 B 29 B 29.4 B 30.7 B 31 B 27.7 B 27 B 26 B 25.3 B 32.3 B 31 B 28.4 B 26.6 B 29.1 B 29 B

Cash and Cash Equivalents

2.79 B 2.4 B 1.87 B 1.17 B 2.3 B 3.23 B 1.42 B 1.69 B 1.94 B 2.33 B 1.77 B - - - -

Book Value

11 B 12 B 12.1 B 30.7 B 31 B 11.9 B - - - - - - - 31.1 B 31.1 B

Total Shareholders Equity

11 B 12 B 12.1 B 13.3 B - 11.9 B 12.6 B 12.1 B 12 B 13.5 B 11.7 B - - - -

All numbers in EUR currency

Quarterly Balance Sheet Koninklijke Philips N.V.

2025-Q4 2024-Q4 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - - - - - - - - - - - - - - 892 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

8.45 B 8.79 B 9.06 B - - - - 9.04 B - - - 8.08 B - - - 7.41 B - - - 5.96 B - - - 6.43 B - - - 8.34 B - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

16 B 16.9 B 17.3 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - - - - - - - - - - - - - - - - 8.27 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

26.9 B 29 B 29.4 B - - - - 31 B - - - 27.7 B - - - 27 B - - - 26 B - - - 25.3 B - - - 32.3 B - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

2.79 B 2.4 B 1.87 B - - - - 2.3 B - - - 3.23 B - - - 1.42 B - - - 1.69 B - - - 1.94 B - - - 2.33 B - - - 1.77 B - - - 1.87 B - - - - - - - - - - - - - - -

Book Value

11 B 12 B 12.1 B - - - - 31 B - - - 27.7 B - - - 27 B - - - 26 B - - - 25.3 B - - - 32.3 B - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

11 B 12 B 12.1 B - - - - 14.5 B - - - 11.9 B - - - 12.6 B - - - 12.1 B - - - 12 B - - - 13.5 B - - - 11.7 B - - - 10.9 B - - - - - - - - - - - - - - -

All numbers in EUR currency

Balance Sheet is a fundamental financial report of Koninklijke Philips N.V., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Diagnostics research

Issuer Price % 24h Market Cap Country
Medpace Holdings Medpace Holdings
MEDP
$ 618.47 1.94 % $ 17.8 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
Celcuity Celcuity
CELC
$ 56.58 0.67 % $ 2.65 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 622.29 0.12 % $ 33.4 B schweizSchweiz
NeoGenomics NeoGenomics
NEO
$ 16.65 2.19 % $ 2.13 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 11.81 0.73 % $ 2.57 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 64.0 3.07 % $ 3.41 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 20.15 3.33 % $ 451 M usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 229.04 3.04 % $ 163 B usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 11.44 2.69 % $ 389 M israelIsrael
Precipio Precipio
PRPO
$ 21.38 1.3 % $ 34.3 M usaUSA
RadNet RadNet
RDNT
$ 68.8 1.81 % $ 5.17 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 31.96 2.08 % $ 926 M usaUSA
Guardant Health Guardant Health
GH
$ 158.6 1.77 % $ 19.9 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 7.77 1.6 % $ 324 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 4.82 0.97 % $ 19.2 M israelIsrael
DexCom DexCom
DXCM
$ 86.04 0.07 % $ 33.6 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 266.9 0.11 % $ 45.9 B usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.18 5.31 % $ 22.6 M singaporeSingapore
Waters Corporation Waters Corporation
WAT
$ 436.95 0.65 % $ 26 B usaUSA
Exagen Exagen
XGN
$ 7.72 1.66 % $ 166 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.25 0.36 % $ 6.81 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 170.18 3.65 % $ 13.3 B irlandaIrlanda
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 4.85 6.81 % $ 3.82 M usaUSA
OPKO Health OPKO Health
OPK
$ 1.53 0.62 % $ 1.15 B usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 690.0 3.46 % $ 260 B usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 132.75 0.45 % $ 7.94 B usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 17.89 0.03 % $ 5.08 B usaUSA
Natera Natera
NTRA
$ 393.44 2.54 % $ 53.8 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
$ 46.13 0.15 % $ 10 B niderlandNiderland
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 8.03 1.26 % $ 2.88 B irlandaIrlanda
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.0 0.36 % $ 26.1 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 560.36 2.41 % $ 45.1 B usaUSA
Personalis Personalis
PSNL
$ 15.65 0.19 % $ 1.4 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 12.91 0.29 % $ 544 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 6.47 2.11 % $ 28.6 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA